A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD)
A legfontosabb adatok
- Ki végzi
- Medical University Innsbruck
- Hol
- Ausztria, Franciaország és Németország6 helyszín, 3 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 48 fő, tervezett
- Kezdés
- 2026. júl. 13.
- Várható befejezés
- 2029. jún. 30.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Obinutuzumab Injection
- Predniso(lo)ne
- A regiszteradat frissítve
- 2026. augusztus 17.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with a first episode of minimal change disease (MCD), a kidney disease that causes heavy protein loss in urine. It compares obinutuzumab with glucocorticoids.
- Életkor
- 18 years or older
- Nem
- Male and female
- A betegség stádiuma
- First episode of nephrotic syndrome from new (de novo) MCD, confirmed by kidney biopsy. Serum albumin <30g/l and UPCR >3g/g creatinine (>300 mg/mmol).
- Korábbi kezelés
- No Predniso(lo)ne during screening. No B cell depleting treatment within 18 months (or 12 months if B cells have returned). No cyclophosphamide within 6 months.
- Biomarker vagy leletérték
- Serum albumin <30g/l and UPCR >3g/g creatinine (>300 mg/mmol). Women who could become pregnant need a negative pregnancy test.
A részvétel fő kizáró okai
- MCD caused by another illness, such as certain cancers, or by drugs like lithium, interferon or NSAIDs
- Current or past hepatitis B, C or HIV infection, unless preventive treatment is given and no active virus is found
- Severe infection needing treatment within 14 days, or severe heart failure (NYHA class III or IV)
- Cancer within the past 5 years, with some exceptions
- Pregnant or breast-feeding women, or a live vaccine in the 4 weeks before screening
A regiszter feltételei, szó szerint
Mind a 20 feltétel megnézéseKevesebb
Ki vehet részt
- Understands and agrees to comply with the study procedures and provides informed consent as documented by signature
- Male or female patients aged 18 years or older at the time of consent
- Confirmed first episode of nephrotic syndrome at trial enrolment (serum albumin <30g/l and UPCR >3g/g creatinine (>300 mg/mmol) secondary to de novo MCD
- Histologically confirmed MCD (latest before randomization to Arm A or B)
- Only applies to women of childbearing potential (WOCBP):; Has a high sensitivity negative urine/serum pregnancy test at screening; Agrees to follow contraceptive guidance until 18 months after 2nd obinutuzumab treatment (if randomized to Arm B)
- Only applies to trial sites in France: Patients affiliated with the French health care system
Ki nem vehet részt
- Family history of MCD or in a first degree relative unless previously shown to be steroid-responsive
- Previous cyclophosphamide within 6 months preceding baseline of the trial
- Treatment with Predniso(lo)ne within screening phase (before randomization)
- Evidence of active severe infection requiring systemic antibacterial, antifungal or antiviral therapy within 14 days prior to first dose of study drug
- Live vaccine administration in the four weeks prior to screening and during the study duration of 52 weeks
- Previous/known hypersensitivity to predniso(lo)ne or obinutuzumab or to any of the excipients to be in accordance with the SmPC of Gazyvaro
- MCD due to secondary causes, including malignancy of a type likely to be associated with MCD (i.e., lymphoproliferative disorders), or potentially related to treatment known to be associated with MCD occurrence (lithium, interferon, non-steroidal anti-inflammatory drugs)
- Evidence of current or past infection with Hepatitis B, C or Human Immunodeficiency Virus (HIV) (unless appropriate prophylaxis is given and no replicating virus is detected)
- Severe heart failure or severe, uncontrolled cardiac disease (NYHA class III or IV)
- Patient with a history of prior malignancy within 5 years before the first dose of study drug. Exceptions may apply for the following: malignancies with a negligible risk of metastasis or death such as adequately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, ductal carcinoma in situ, or Stage I uterine cancer
- Previous B cell depletion, independent of the agent and treatment target (i.e., CD20, CD38, etc.), within 18 months preceding baseline of the trial, or 12 months if there is evidence of B cell return in peripheral lymphocyte subsets
- Pregnant or breast-feeding women
- Co-enrolment in another clinical trial of an investigational medicinal product
- Any other reason which, in the opinion of the Principal Investigator (PI), renders the patient unsuitable for the trial
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
3 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
OBELIX-NEPHROSIS (NS)
A teljes eredeti leírásKevesebb
The goal of this clinical trial is to learn if obinutuzumab works to treat minimal change disease in adults. It will also learn about the safety of drug obinutuzumab. The main questions it aims to answer are:
Is obinutuzumab non-inferior to glucocorticoids at inducing remission? Does obinutuzumab provide superiority in terms of relapse-free survival after 52 weeks? What medical problems do participants have when receiving obinutuzumab? Researchers will compare drug obinutuzumab to glucocorticoids and aim to phenotype participants with minimal change disease.
Participants will:
Take the drug obinutuzumab (2 doses) or glucocorticoids Visit the clinic for 8 visits over a period of 52 weeks, plus additional controls when disease relapses occur
A vizsgálat 2 csoportja
- ObinutuzumabA vizsgált kezelés
Kezelés: Obinutuzumab Injection
- GlucocorticoidsMár használt kezelés, összehasonlításként
Kezelés: Predniso(lo)ne
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Randomized Controlled, Two-arm (1:1 Ratio) Phase IIa Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With de Novo Minimal Change Disease
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- A regiszteradat frissítve
- 2026. augusztus 17.